768-19-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl[1,2,4]triazolo[1,5-a]pyridine is utilized as an intermediate in the synthesis of pharmaceutical compounds. Its unique structure and biological activity make it a promising candidate for the development of new drugs, particularly in the context of drug discovery research.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 2-Methyl[1,2,4]triazolo[1,5-a]pyridine serves as an intermediate for the synthesis of various agrochemicals. Its application in this field highlights its versatility and the potential for creating innovative solutions for agricultural challenges.
Used in Drug Discovery Research:
2-Methyl[1,2,4]triazolo[1,5-a]pyridine is employed as a valuable building block in drug discovery research. Its unique molecular properties and demonstrated biological activity contribute to the exploration of new therapeutic agents, making it an essential component in the advancement of medical science.

Upstream product

• 56536-36-8 N-pyridin-2-yl-acetamidine 
• 546-67-8 lead(IV) tetraacetate 
• 71-43-2 benzene 
• 6295-87-0 N-aminopyridin-1-ium iodide 
• 75-05-8 acetonitrile 

Relevant academic research and scientific papers

1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors with a Novel Monodentate Binding Interaction

Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe2+ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties.

BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s); R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s); Xa and Xb are each C, N, O or S; Xc and Xd are each C or N; m is 0-2; n is 1-3; ring A is a 5-membered ring optionally having substituent(s); ring B is a 6-membered ring optionally having substituent(s); and ring C is a 3- to 5-membered ring optionally having substituent(s), provided that when Xa, Xc and Xd are each C, then Xb is N or S, or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.